RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern
文献类型：期刊论文
| 作者 | Zhou, Shi-Hao1; Zhang, Ru-Yan1; Zhang, Hai-Wei2; Liu, Yan-Ling1; Wen, Yu1; Wang, Jian1; Li, Yu-Ting1; You, Zi-Wei1; Yin, Xu-Guang1; Qiu, Hong3 |
| 刊名 | CHEMICAL COMMUNICATIONS
 |
| 出版日期 | 2022-02-10 |
| 卷号 | 58期号:13页码:2120-2123 |
| ISSN号 | 1359-7345 |
| DOI | 10.1039/d1cc06520c |
| 通讯作者 | Gong, Rui(gongr@wh.iov.cn) ; Yang, Guang-Fu(gfyang@mail.ccnu.edu.cn) ; Guo, Jun(jguo@mail.ccnu.edu.cn) |
| 英文摘要 | The coronavirus 2019 (COVID-19) pandemic is causing serious impacts in the world, and safe and effective vaccines and medicines are the best methods to combat the disease. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein plays a key role in interacting with the angiotensin-converting enzyme 2 (ACE2) receptor, and is regarded as an important target of vaccines. Herein, we constructed the adjuvant-protein conjugate Pam(3)CSK(4)-RBD as a vaccine candidate, in which the N-terminal of the RBD was site-selectively oxidized by transamination and conjugated with the TLR1/2 agonist Pam(3)CSK(4). This demonstrated that the conjugation of Pam(3)CSK(4) significantly enhanced the anti-RBD antibody response and cellular response. In addition, sera from the Pam(3)CSK(4)-RBD immunized group efficiently inhibited the binding of the RBD to ACE2 and protected cells from SARS-CoV-2 and four variants of concern (alpha, beta, gamma and delta), indicating that this adjuvant strategy could be one of the effective means for protein vaccine development. |
| WOS关键词 | COVID-19 ; PROTEIN |
| 资助项目 | National Natural Science Foundation of China[21772056] ; National Natural Science Foundation of China[22177035] ; National Key Research and Development Program of China[2017YFA0505200] ; Wuhan Bureau of Science and Technology[2020020601012217] ; Wuhan Bureau of Science and Technology[2020020101010001] ; Selfdetermined Research Funds of CCNU from the Colleges' Basic Research and Operation of MOE[CCNU20TS016] ; Program of Introducing Talents of Discipline to Universities of China[B17019] |
| WOS研究方向 | Chemistry |
| 语种 | 英语 |
| 出版者 | ROYAL SOC CHEMISTRY |
| WOS记录号 | WOS:000743628900001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/300525]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Gong, Rui; Yang, Guang-Fu; Guo, Jun |
| 作者单位 | 1.Cent China Normal Univ, Hubei Int Sci & Technol Cooperat Base Pesticide &, Int Joint Res Ctr Intelligent Biosensing Technol, Minist Educ,Coll Chem,Key Lab Pesticide & Chem Bi, Wuhan 430079, Peoples R China 2.Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, CAS Key Lab Special Pathogens & Biosafety, Wuhan 430071, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhou, Shi-Hao,Zhang, Ru-Yan,Zhang, Hai-Wei,et al. RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern[J]. CHEMICAL COMMUNICATIONS,2022,58(13):2120-2123. |
| APA | Zhou, Shi-Hao.,Zhang, Ru-Yan.,Zhang, Hai-Wei.,Liu, Yan-Ling.,Wen, Yu.,...&Guo, Jun.(2022).RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern.CHEMICAL COMMUNICATIONS,58(13),2120-2123. |
| MLA | Zhou, Shi-Hao,et al."RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern".CHEMICAL COMMUNICATIONS 58.13(2022):2120-2123. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。